Human immunodeficiency virus-associated Hodgkin lymphoma: a clinical analysis of 22 cases
10.3760/cma.j.cn115356-20230519-00118
- VernacularTitle:人类免疫缺陷病毒相关霍奇金淋巴瘤22例临床分析
- Author:
Chaoyu WANG
1
;
Jun LIU
;
Dehong HUANG
;
Jieping LI
;
Yao LIU
Author Information
1. 重庆大学附属肿瘤医院血液肿瘤中心 肿瘤转移与个体化诊治转化研究重庆市重点实验室，重庆 400030
- Keywords:
Acquired immunodeficiency syndrome;
Hodgkin lymphoma;
Treatment outcome;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2024;33(1):48-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics, therapeutic efficacy and prognosis of patients with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.Methods:A retrospective case series study was conducted. The clinical data of 22 HIV-associated Hodgkin lymphoma patients in Chongqing University Cancer Hospital from December 2013 to June 2022 were retrospectively analyzed. Their clinical features, laboratory results, treatment, and prognosis were analyzed. Kaplan-Meier method was used to perform survival analysis.Results:The age [ M ( Q1, Q3)] of 22 patients was 44 years old (36 years old, 53 years old); 18 cases were male, 4 cases were female; clinical staging was stage Ⅲ in 5 patients and stage Ⅱ in 17 patients. All 22 patients were infected with HIV through sexual transmission, with 10 cases transmitted through man sex with man and 12 cases transmitted through heterosexual transmission. Nine patients were found to be infected with HIV at the time of diagnosis of lymphoma, and 13 patients presented with lymphoma at 22.2 months (12.3 months, 38.4 months) after diagnosis of HIV infection. Of the 22 patients, 3 abandoned treatment; 19 patients were treated with antiretroviral therapy combined with ABVD regimen chemotherapy, 9 patients had complete remission, and 10 patients had partial remission. After follow-up of 46.8 months (24.8 months, 64.5 months), the 5-year progression-free survival rate was 83.9%, and the 5-year overall survival rate was 89.5%. Conclusions:HIV-associated Hodgkin lymphoma exhibits an invasive process in clinical practice, and standardized antiretroviral therapy combined with ABVD regimen chemotherapy can lead to long-term survival for patients.
